Beyond PSMA: Expanding the Theranostic Horizon

Beyond PSMA: Expanding the Theranostic Horizon

PSMA-targeted radiopharmaceuticals have brought theranostics into the clinical spotlight—but what comes next? In this episode, host Dr. Mike Nickels is joined by Dr. Anna Wu (City of Hope) for a wide-ranging discussion on the future of theranostics beyond PSMA. Together, they explore what makes a strong theranostic target, how evolving tumor biology and heterogeneity are shaping next-generation agents, and why pan-cancer and tumor-microenvironment targets are gaining momentum. The conversation also dives into combination strategies, alpha-emitters, clinical translation challenges, and what the next decade may hold for the field. A must-listen for scientists, clinicians, and anyone interested in where theranostics is headed next.

Global Access & Innovation, Part 1: A Conversation on Point-of-Care Technologies in Molecular Imaging

Host Arvind Pathak, PhD (Johns Hopkins University) speaks with Rebecca Richards-Kortum, PhD (Rice University) about how point-of-care technologies are expanding access to early detection and diagnosis in low-resource settings. They discuss innovations in optical imaging, the role of machine learning, real-world lessons from cervical cancer screening programs, and why sustainable training and local partnerships are essential for global impact.

Canada’s Nuclear Leadership in Isotopes

This special episode, produced in collaboration with the Canadian Nuclear Isotope Council (CNIC), features James Scongack - the CNIC’s Chair and COO of Bruce Power - discussing Canada’s global leadership in medical isotope production. From cobalt-60 to lutetium-177, learn how Canada is investing in infrastructure, building cross-border partnerships, and scaling up to meet the growing demand for radiotheranostics.

Isotope Supply: Can Theranostics Scale?

In this episode, Dr. Cathy Cutler of Brookhaven National Lab joins host Dr. Mike Nickels to explore one of the most pressing questions in nuclear medicine today: can theranostics scale? From supply chain challenges for key isotopes like Lu-177, Ac-225, and Cu-67 to infrastructure gaps, regulatory hurdles, and international collaboration, this wide-ranging conversation highlights both the urgency and opportunity in building a robust isotope supply for the future of targeted radiopharmaceutical therapy.

Theranostics in the Clinic: What’s Working, What’s Missing, and What’s Next

In this episode, Dr. Lilja Solnes (Johns Hopkins) and Dr. Martin Pomper (UT Southwestern) explore the current landscape of theranostics in clinical practice, from the early days of targeted radiopharmaceuticals to today’s breakthroughs and future directions. They discuss the success of agents like Lutathera and Pluvicto, the importance of preclinical models, the rise of alpha emitters, and the potential of combination therapies. With candid reflections on what’s working, what’s missing, and how to bridge the gap between research and patient care, this conversation offers deep insights into the evolving role of molecular imaging and therapy.